Beth Reid, MD
Obstetrics & Gynecology · San Marcos, TXNPI 1619975430
Payments from drug & device makers
Across 127 payments — averaging $19.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mayne Pharma Commercial LLC$374
- AbbVie$298
- Millicent US Inc$206
- Astellas Pharma US Inc$184
- Therapeuticsmd, Inc.$180
- Sumitomo Pharma America, Inc.$157
- plus $1K from 20 others
What the payments were for
- Food & beverage$2,21891%
- Education$2329%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mayne Pharma Commercial LLC | 16 | $374 |
| AbbVie | 17 | $298 |
| Millicent US Inc | 5 | $206 |
| Astellas Pharma US Inc | 7 | $184 |
| Therapeuticsmd, Inc. | 13 | $180 |
| Sumitomo Pharma America, Inc. | 7 | $157 |
| Agile Therapeutics, Inc. | 8 | $136 |
| Exeltis, USA Inc. | 7 | $120 |
| Avion Pharmaceuticals | 6 | $98 |
| Organon | 8 | $98 |
| Intuitive Surgical | 1 | $86 |
| Biogen | 4 | $85 |
| Coopersurgical, Inc. | 3 | $81 |
| Pfizer | 3 | $64 |
| Myovant Sciences Inc. | 3 | $61 |
| Avanos Medical | 2 | $37 |
| Shield Therapeutics Inc | 2 | $36 |
| Urovant Sciences Inc | 2 | $34 |
| Aspira Women's Health Inc | 2 | $25 |
| Dexcom, Inc. | 1 | $21 |
| Axonics, Inc. | 1 | $20 |
| Mimedx Group, Inc. | 1 | $16 |
| Mylan Pharmaceuticals Inc. | 1 | $14 |
| Mission Pharmacal Company | 1 | $12 |
| Evofem Biosciences, Inc. | 1 | $10 |
| Unified Women's Healthcare, LP | 5 | $0 |
How this compares
$2,450 in reported general payments places this provider in the 70th percentile of 3,099 obstetrics & gynecology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 91 | $10,233 |
| YuvafemEstradiol | 26 | $5,744 |
| Estradiol (Twice Weekly)Estradiol | 17 | $1,989 |
| ProgesteroneProgesterone, Micronized | 22 | $1,814 |
| ValacyclovirValacyclovir Hcl | 17 | $581 |
| Clobetasol Propionate | 18 | $248 |
Paid to pharmacies, not to this prescriber.
Other obstetrics & gynecology in San Marcos
- Amir JazaeriHouston$19.5M
- Shannon WestinHouston$17.3M
- Monica LopezFort Worth$8.1M
- Cynthia RobbinsFort Worth$7.8M
- John Paul RobertsPlano$4.9M
- Stephen StamatisWeatherford$4.5M
- Parke HedgesSan Antonio$4.2M
- Mary MartinBeaumont$2.8M
- Mark JacobsHouston$2.8M
- Dawnette PepplerArlington$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.